Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders

Detalhes bibliográficos
Autor(a) principal: Fonseca-Hial,Ana Marcela Rojas
Data de Publicação: 2016
Outros Autores: Parisio,Katya, Oliveira,Jose Salvador Rodrigues
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista brasileira de hematologia e hemoterapia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842016000200099
Resumo: ABSTRACT BACKGROUND: The role of allogeneic hematopoietic stem cell transplantation for advanced indolent lymphoproliferative disorders remains to be established. OBJECTIVE: This paper aims to describe the results of allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders. METHODS: This article reports on 29 adult patients submitted to allogeneic transplantations from 1997 to 2010. RESULTS: Most had follicular non-Hodgkin lymphoma (n = 14) or chronic lymphocytic leukemia (n = 12). The median age was 44 years (range: 24-53 years) and 65% of patients were male. Only 21% had had access to rituximab and 45% to fludarabine. All had advanced disease (stage IV) with partial response or stable disease. Most underwent myeloablative conditioning n = 17 - 59%). In this scenario, refractory disease was observed in seven (24%) patients, the 100-day mortality rate was 17% (n = 5) and relapse occurred in four patients (18%). The main cause of death throughout the follow up was refractory disease in six of the 12 patients who died. Moderate and severe chronic graft-versus-host disease was frequent; about 41% of 24 patients analyzed. The overall survival rates and disease free survival at 42 months were 56.7% and 45.4%, respectively. According to Kaplan-Meyer analysis, the median time from diagnosis to transplant predicted the overall survival; however age, gender and conditioning regimen did not predict the prognosis. It was impossible to reach other conclusions because of the small sample size in this study. CONCLUSIONS: The role of allogeneic transplantations should be re-evaluated in the era of targeted therapy.
id ABHHTC-1_7566ec1cc1c1f56e909243f693256fba
oai_identifier_str oai:scielo:S1516-84842016000200099
network_acronym_str ABHHTC-1
network_name_str Revista brasileira de hematologia e hemoterapia (Online)
repository_id_str
spelling Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disordersHematopoietic stem cell transplantIndolent lymphoproliferative disorderReduced intensity conditioningGraft-versus-lymphomaAllogeneicABSTRACT BACKGROUND: The role of allogeneic hematopoietic stem cell transplantation for advanced indolent lymphoproliferative disorders remains to be established. OBJECTIVE: This paper aims to describe the results of allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders. METHODS: This article reports on 29 adult patients submitted to allogeneic transplantations from 1997 to 2010. RESULTS: Most had follicular non-Hodgkin lymphoma (n = 14) or chronic lymphocytic leukemia (n = 12). The median age was 44 years (range: 24-53 years) and 65% of patients were male. Only 21% had had access to rituximab and 45% to fludarabine. All had advanced disease (stage IV) with partial response or stable disease. Most underwent myeloablative conditioning n = 17 - 59%). In this scenario, refractory disease was observed in seven (24%) patients, the 100-day mortality rate was 17% (n = 5) and relapse occurred in four patients (18%). The main cause of death throughout the follow up was refractory disease in six of the 12 patients who died. Moderate and severe chronic graft-versus-host disease was frequent; about 41% of 24 patients analyzed. The overall survival rates and disease free survival at 42 months were 56.7% and 45.4%, respectively. According to Kaplan-Meyer analysis, the median time from diagnosis to transplant predicted the overall survival; however age, gender and conditioning regimen did not predict the prognosis. It was impossible to reach other conclusions because of the small sample size in this study. CONCLUSIONS: The role of allogeneic transplantations should be re-evaluated in the era of targeted therapy.Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular2016-06-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842016000200099Revista Brasileira de Hematologia e Hemoterapia v.38 n.2 2016reponame:Revista brasileira de hematologia e hemoterapia (Online)instname:Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)instacron:ABHHTC10.1016/j.bjhh.2016.02.006info:eu-repo/semantics/openAccessFonseca-Hial,Ana Marcela RojasParisio,KatyaOliveira,Jose Salvador Rodrigueseng2016-06-29T00:00:00Zoai:scielo:S1516-84842016000200099Revistahttp://www.rbhh.org/pt/archivo/https://old.scielo.br/oai/scielo-oai.phpsbhh@terra.com.br||secretaria@rbhh.org1806-08701516-8484opendoar:2016-06-29T00:00Revista brasileira de hematologia e hemoterapia (Online) - Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)false
dc.title.none.fl_str_mv Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders
title Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders
spellingShingle Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders
Fonseca-Hial,Ana Marcela Rojas
Hematopoietic stem cell transplant
Indolent lymphoproliferative disorder
Reduced intensity conditioning
Graft-versus-lymphoma
Allogeneic
title_short Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders
title_full Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders
title_fullStr Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders
title_full_unstemmed Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders
title_sort Allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders
author Fonseca-Hial,Ana Marcela Rojas
author_facet Fonseca-Hial,Ana Marcela Rojas
Parisio,Katya
Oliveira,Jose Salvador Rodrigues
author_role author
author2 Parisio,Katya
Oliveira,Jose Salvador Rodrigues
author2_role author
author
dc.contributor.author.fl_str_mv Fonseca-Hial,Ana Marcela Rojas
Parisio,Katya
Oliveira,Jose Salvador Rodrigues
dc.subject.por.fl_str_mv Hematopoietic stem cell transplant
Indolent lymphoproliferative disorder
Reduced intensity conditioning
Graft-versus-lymphoma
Allogeneic
topic Hematopoietic stem cell transplant
Indolent lymphoproliferative disorder
Reduced intensity conditioning
Graft-versus-lymphoma
Allogeneic
description ABSTRACT BACKGROUND: The role of allogeneic hematopoietic stem cell transplantation for advanced indolent lymphoproliferative disorders remains to be established. OBJECTIVE: This paper aims to describe the results of allogeneic hematopoietic stem cell transplantation in patients with advanced indolent lymphoproliferative disorders. METHODS: This article reports on 29 adult patients submitted to allogeneic transplantations from 1997 to 2010. RESULTS: Most had follicular non-Hodgkin lymphoma (n = 14) or chronic lymphocytic leukemia (n = 12). The median age was 44 years (range: 24-53 years) and 65% of patients were male. Only 21% had had access to rituximab and 45% to fludarabine. All had advanced disease (stage IV) with partial response or stable disease. Most underwent myeloablative conditioning n = 17 - 59%). In this scenario, refractory disease was observed in seven (24%) patients, the 100-day mortality rate was 17% (n = 5) and relapse occurred in four patients (18%). The main cause of death throughout the follow up was refractory disease in six of the 12 patients who died. Moderate and severe chronic graft-versus-host disease was frequent; about 41% of 24 patients analyzed. The overall survival rates and disease free survival at 42 months were 56.7% and 45.4%, respectively. According to Kaplan-Meyer analysis, the median time from diagnosis to transplant predicted the overall survival; however age, gender and conditioning regimen did not predict the prognosis. It was impossible to reach other conclusions because of the small sample size in this study. CONCLUSIONS: The role of allogeneic transplantations should be re-evaluated in the era of targeted therapy.
publishDate 2016
dc.date.none.fl_str_mv 2016-06-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842016000200099
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842016000200099
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1016/j.bjhh.2016.02.006
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular
publisher.none.fl_str_mv Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular
dc.source.none.fl_str_mv Revista Brasileira de Hematologia e Hemoterapia v.38 n.2 2016
reponame:Revista brasileira de hematologia e hemoterapia (Online)
instname:Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)
instacron:ABHHTC
instname_str Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)
instacron_str ABHHTC
institution ABHHTC
reponame_str Revista brasileira de hematologia e hemoterapia (Online)
collection Revista brasileira de hematologia e hemoterapia (Online)
repository.name.fl_str_mv Revista brasileira de hematologia e hemoterapia (Online) - Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)
repository.mail.fl_str_mv sbhh@terra.com.br||secretaria@rbhh.org
_version_ 1754213112801656833